Dear Voornaam,

Recent findings have revealed the heterogeneous nature of glioblastoma, and many researchers are looking at ways to navigate the incredible complexity to find a genomic route to develop effective treatments. But could a developmental approach lead to a common target?

Steve Pollard is co-director of our Glioma Brain Tumour Centre of Excellence. Steve and colleagues are trying to understand how to stimulate the immune system for more effective and durable responses.

Hear what Steve has to say about the most promising therapeutic approaches, applying new ideas from computational biology and AI, and the major obstacles standing in the way of effective glioblastoma treatments.

£24m to enable innovative radiation research

We’re renewing our investment in radiobiology and radiation oncology research with a further £24m over five years to support a network of seven specialised Radiation Research Centres of Excellence.

Radiobiology is one of the UK’s research strengths and has been elevated by our network since 2019. Our City of London, Manchester, Institute of Cancer Research and Royal Marsden Hospital, Leeds, Glasgow and Cambridge centres will maintain their research infrastructure and RadNet Centre status, whilst Birmingham will be the newest centre to join them in enabling innovative internationally leading radiation research.

C-Further: expression of interest deadline tomorrow

If you have an early-stage therapeutic or validation target for children’s and young people’s cancers, C-Further wants to hear from you.

Submit your proposal for the opportunity to partner with C-Further and gain access to cutting-edge drug discovery facilities, expert support, funding and resources to advance your therapeutic asset into novel medicines.

There is a rolling call for expressions of interest to collaborate with C-Further. The first deadline is on 1 November 2024.